Plain-English translation of NCT07530770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a medication called benralizumab to see if it can help people who have severe asthma combined with a fungal lung condition. The condition, called allergic bronchopulmonary aspergillosis (ABPA), happens when your airways react too strongly to a common mold. Researchers want to know if this medication can improve your symptoms and keep your lungs healthier.
Severe asthma combined with this fungal lung condition is very hard to treat with standard asthma medicines alone, and many patients still have frequent flare-ups and breathing problems. This trial will help doctors understand whether this new medication can offer better control for people dealing with both conditions at the same time.
You likely qualify if…
You likely don't qualify if…
You will receive four injections of the medication over 16 weeks — three injections spaced 4 weeks apart, followed by one final injection 8 weeks later. After your last injection, you will have a follow-up visit 8 weeks later to check how you are doing. The entire study lasts 24 weeks from start to finish.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
Qianfoshan Hospital
Enrollment target
~20 participants
Started
September 2025
Primary completion
July 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qian Qi, Dr.
Shandong First Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.